2022 Wrap Up

As we got through the height of the pandemic in 2021 and moved into 2022, we believed that it would be a year of hope. And thanks to the support of our incredible community of donors, volunteers, supporters – we surpassed even our wildest expectations.

We opened the year with one of our biggest undertakings as an organization – our Let’s Make History Again fundraising event in support of our $100 Million Campaign to Accelerate. Five flagpoles and Leaders of History, four cities, 100 Ambassador of History families camping in the cold winter in solidarity. This was spearheaded by a passionate and dedicated JDRF volunteer, Peter Oliver, who himself camped atop a flagpole 30 years before, and whose daughter Vanessa was one of our Leaders in History in April. Sadly, Peter passed away in September, but we carry his spirit and devotion to finding cures for type 1 diabetes with us in everything we do. We are so grateful to our many volunteers, corporate sponsors and staff for taking Peter’s vision and making it reality.  Read more about Peter Oliver’s incredible legacy.

Click here to watch a video of this incredible event

Our community rallied in ways that we could not imagine, and it only continued throughout the year. Thanks to our JDRF supporters, we were able to continue advancing the most promising type 1 diabetes (T1D) research getting us closer to cures, while improving the lives of people affected by T1D today.

Thanks to the generosity of donors, JDRF had another ground-breaking year– dedicating more dollars to research, strengthening our strategic partnerships, continuing to support newly diagnosed families, and sharing the latest research updates with our community.

Some highlights over the past year included:
In T1D research:

In Cell Replacement:

In Disease-Modifying Therapies:

  • Teplizumab was approved by the FDA in the USA. This drug has shown great promise as the first ever disease-modifying therapy for T1D, as it has been shown to significantly delay the onset of T1D.

In Treatments to Improve Lives:

  • JDRF-funded researchers are performing advanced clinical trials on a once-daily therapeutic drug that restores glucagon secretion to prevent hypoglycemia, and if approved would be the first drug of its kind for people with type 1 diabetes.
  • Funding programs devoted to improving mental health care and outcomes for people with T1D, including REACHOUT.

In Screening:

To read more about research updates, please visit www.jdrf.ca/blog to see more stories about the incredible progress that took place over the last year in type 1 diabetes research and development.

It has never been a more exciting time in diabetes research and at JDRF. And together with our JDRF community, we believe that a world free from type 1 diabetes is closer than ever.

Stay connected on the latest